NuMA, a 238 kDa protein present in the nucleus during interphase, translocates to the spindle poles in mitosis. NuMA plays an essential role in mitosis, since microinjection of the NuMA SPN-3 monoclonal antibody causes mitotic arrest and micronuclei formation. We have mapped the approximate position of the epitopes of six monoclonal NuMA antibodies using recombinant NuMA fragments. The SPN-3 epitope has been located to residues 255-267 at the C-terminus of the first helical subdomain of the central rod domain and several residues crucial for antibody binding have been identified. To gain insight into the ultrastructure of NuMA, several defined fragments, as well as the fulllength recombinant protein, were expressed in Escherichia coli and purified to homogeneity. They were then characterized by chemical cross-linking, circular dichroism spectra and electron microscopy. The results directly reveal the tripartate structure of NuMA. A long central rod domain is flanked by globular end domains. The rod is 207 nm long and is at least 90% a-helical. It reflects a double-stranded coiled-coil with the ax-helices arranged parallel and in register. The NuMA protein thus forms the longest coiled-coil currently known. Our analyses reveal no indication that recombinant NuMA assembles into filaments or other higher order structures.
Introduction
The nuclear mitotic apparatus protein (NuMA) changes its cellular location in a cell cycle-specific manner. In interphase NuMA is associated with the nuclear matrix (Lydersen and Pettijohn, 1980; Price and Pettijohn, 1986; Kallajoki et al., 1991) . In mitosis it relocates to the spindle poles. NuMA has been cloned and fully sequenced (Compton et al., 1992; Maekawa and Kuriyama, 1993; Tang et al., 1993) . These sequences, as well as partial nucleotide or amino acid sequences from other laboratories, show that a variety of other antigens originally given different names are in fact the NuMA molecule. These include SPN (Kallajoki et al., 1991 (Kallajoki et al., , 1993 , SP-H (Maekawa et al., 1991) , centrophilin (Tousson et al., 1991) , WI (Tang et al., 1993) and lH1/IFl (Compton et al., 1991) .
Micronucleation and mitotic arrest as consequences of injection of a NuMA antibody were first described for the SPN-3 antibody. Approximately 50% of HeLa cells became micronucleated after injection of SPN-3 antibodies and this effect was seen at antibody concentrations as low as 300 gg/ml. The other 50% became blocked in mitosis and displayed aberrant spindles, as judged by staining with tubulin antibodies. These results allowed us to conclude that the NuMA/SPN antigen plays a functional role in mitosis (Kallajoki et al., 1991 (Kallajoki et al., , 1993 . Other evidence arguing that this is the case includes the demonstration by that injection of a rabbit NuMA antibody into cells in early mitotic stages prevented spindle formation, while injection into metaphase cells caused the collapse of the mitotic spindle. Compton and Cleveland (1993) have shown that the defect in the hamster cell line tsBN2, which forms micronuclei at the restrictive temperature, can be rescued by expression of human NuMA. These authors have also shown that transfection of hamster BHK-21 cells with cDNA constructs encoding truncated forms of the human NuMA protein can lead to micronucleation. Thus there is substantial evidence from several laboratories that a correctly functioning NuMA protein is essential for mitosis and nuclear reformation.
Secondary structure prediction rules indicate that the NuMA polypeptide should have a very long a-helical domain flanked by non-helical terminal domains (Compton et al., 1992; . In this respect NuMA is similar to the molecules that constitute the building blocks of the cytoplasmic intermediate filaments and of the nuclear lamins (Fuchs and Weber, 1994) .
Our objectives in the work described here were threefold. First, to identify the exact position of the epitope of the SPN-3 monoclonal antibody along the NuMA polypeptide chain and compare it with that of other NuMA antibodies which do not result in aberrant spindle formation or in micronuclei formation when injected into cells. Second, to decide whether NuMA indeed belongs to the coiled-coil proteins and the number and arrangements of the helices used to build the putative coiled-coil. Third, to describe the ultrastructure of purified NuMA (Compton et al., 1992; 
Results
Isolation of cDNA clones covering the entire human NuMA protein
The central part of Figure 1 indicates the organization of the NuMA molecule inferred from its sequence and from the use of secondary structure prediction rules (Compton et al., 1992; . Numbering is according to . The predicted structure of the NuMA molecule includes a long central a-helical region interrupted at six different points by one or more proline residues. This region is flanked by putative globular head and tail domains. Figure 1 also shows the relative positions of the cDNA constructs and the recombinant protein fragments used in this study. The cDNA clones Uni and Xl-5 were isolated by screening plaques from two commercially available HeLa cell expression libraries with a mixture of six NuMA monoclonal antibodies (SPN-1 to -5 and SPN-7) (Kallajoki et al., 1991) . Two clones from the Uni-Zap XR library (out of 1 200 000 phages plated) and five clones from the k Zap II library (out of 600 000 phages plated) which reacted positively with the antibody mixture were selected for further characterization. DNA sequencing showed that the two clones from the Uni-Zap library were identical. The Uni clone and the XI clone were fully sequenced, while for the other X clones sufficient sequences were obtained to establish the clone boundaries shown in the top part of Figure 1 . The regions that we sequenced ( Figure 1 , solid lines) were all identical with the NuMA sequence of . Each cDNA clone was purified and expressed as a P-galactosidase (x-gal) fusion protein in E.coli.
Several mutants of the kl clone (Xla-d), the X2 clone (k2a-c) and the Uni clone (A5) were generated using PCR and cloned into pRSET expression plasmids. This allowed bacterial expression of a set of fusion proteins corresponding to the different structural domains of the NuMA molecule. Thus the Xlb fragment covers the head domain, which is predicted to be globular, while the Xlc fragment includes only the part of thought to form an a-helix. The k2b fragment covers the part of X2 thought to be a-helical, while the k2c fragment spans the tail region, which is thought to be a globular domain. These constructs are shown diagrammatically in the lower part of Figure 1 . To construct the full-length NuMA cDNA we used a unique BstEII site located within the overlapping region of the Xl and X2 clones. The appropriate fragments were generated and cloned into the pRSET expression vector, as described in Materials and methods.
Position of the epitopes recognized by the different SPN antibodies Escherichia coli extracts expressing NuMA derivates either as n-gal or as pRSET fusion proteins were tested in a dot blot with each of the six SPN/NuMA antibodies (Table I) . For example, in the first test against the n-gal -2, -3, -4 and -7 epitopes (top) and the precise position of the SPN-3 epitope (bottom) along the NuMA polypeptide. Epitopes, marked by horizontal bars, were located approximately using the results in Table I . The precise location of the SPN-3 epitope was obtained from the reactivity of the recombinant fragments in Figure 3 and of the synthetic peptides in Table II . The SPN-3 antibody reacted with the protein product of the N3 clone. Its sequence of 33 amino acids was determined and is given at the bottom of the figure. Using the series of overlapping synthetic peptides shown in Table II Figure 2) . Similarly, the results in Table I allow the SPN-4 epitope to be located to the region between amino acid residues 199 and 216 of the NuMA molecule, i.e. to the extreme C-terminus of the globular head domain. The SPN-7 epitope lies between residues 1613 and 1700 at the C-terminus of the coiled-coil region.
Since SPN-5 reacted with kla, but not with Xlb, Alc or kld, the epitope of this antibody either lies at the junction of klb and Xlc or, alternatively, it is a non-linear epitope.
The smallest of the original NuMA clones recognized by the SPN-3 antibody is the Uni-clone (amino acids 122-432, Table I ). Since SPN-3 reactivity is retained by Xlc and kl d, which both start at residue 216, the SPN-3 epitope must lie between residues 216 and 432. Information on epitopes of the different SPN antibodies, derived from the data in Table I , is shown in the top part of Figure 2 .
Determination of the epitope recognized by the SPN-3 antibody The SPN-3 antibody, but not the SPN-1, -2, -4 or -5 antibodies, caused aberrant spindle formation and micronuclei formation when microinjected into HeLa cells (Kallajoki et al., 1991 (Kallajoki et al., , 1992 (Kallajoki et al., , 1993 . Therefore, the exact location of the SPN-3 epitope was of particular interest. The strategy used to identify it is shown in Figure 3 and ASPLEPKELE, which spans residues 247-279 in the NuMA sequence. Thus the SPN-3 epitope locates to a region which spans the C-terminal half of the first putative coiled-coil segment and the adjacent linker sequence of the NuMA rod domain (see lower part of Figure 2 ). The dots in Figure 2 indicate the residues in the heptad positions a and d, which participate in the putative coiledcoil formation. To confirm this epitope location further, the N3 fragment (NuMA residues 247-279) was expressed as a fusion protein using pRSET A and isolated by nickelnitrilotriacetate (Ni-NTA) affinity chromatography ( Figure  3B , lanes 4 and 5). The purified N3 fragment reacted with the SPN-3 antibody ( Figure 3B , lane 6). Amino acid sequence analysis using lysine protease-derived peptides and CNBr fragments confirmed the presence of NuMA residues 247-279 (data not shown). Synthetic peptides. The SPN-3 epitope was further delineated using a series of overlapping synthetic peptides covering the N3 fragment (residues 247-279) (Table  II) . In the first set of experiments three peptides were synthesized: peptide I (residues 247-264), peptide 2 (residues 255-271) and peptide 3 (residues 262-279). In dot blots of the peptides coupled to ovalbumin, only peptide 2 reacted with the SPN-3 antibody. In a competitive ELISA with the NuMA kla fragment (amino acid residues 1-851), again only peptide 2 showed a strong reaction with the SPN-3 antibody, while peptides 1 and 3 did not. Thus the SPN-3 epitope must be within residues 255-271 (Table II ). In the second set of experiments synthetic peptides with deletions at either the N-terminal or the Cterminal side of peptide 2 were used. Of the three different N-terminal derivatives, only peptide 9 reacted with SPN-3 in the dot blot. This peptide also showed competitive inhibition with the kla fusion protein in the ELISA assay (Table II) . Of the four C-terminal derivatives shown in Table I ). The overlapping subclones Al-A5 were generated by PCR from the Uni clone. The A2 clone (amino acids 199-306) was the smallest derivative retaining SPN-3 reactivity. The overlapping subclones Nl-N7 were generated by PCR from the A2 derivative. N3 (amino acids 247-279) was the smallest construct which when expressed reacted positively with SPN-3. Clones are indicated as horizontal bars and the corresponding terminal residues of the NuMA sequence are indicated. Reactivities of the pRSET fusion proteins (Al-A5 and Nl-N7) with the SPN-3 antibody are indicated on the right. The position of the 33 residues of the N3 protein in the NuMA sequence is shown in Figure 2 . All constructs shown in (A) were expressed in Ecoli and separated on tricine-SDS-PAGE. 
used synthetic peptides with a single amino acid replacement in each of the 13 residues of the NuMA sequence covering residues 255-267. The mutant peptides were assayed with SPN-3 in the dot blot assay or in a competitive ELISA (Table II) . As shown in Table II and summarized in Figure 4 , various positions (Q256, R257, 1258, L261, L263, L264 and E266) could be replaced by alanine without loss of antibody reactivity, which is often found in a-helices forming coiled-coils. In the case of D259 and R260, replacement by alanine abolished SPN-3 reactivity, while replacement of Q255 and K267 led to reduced reactivity. More striking were the results of the conservative replacements of D259 and R260 by glutamic acid and lysine respectively, which led to a loss of antibody reactivity (Table II , Figure 4 ). Other mutations which abolished antibody reactivity involved the replacement of the three leucines by glutamic acid, while I258 could be substituted by glutamic acid without loss of reactivity. In summary, the SPN-3 epitope (residues 255-267) lies towards the N-terminal end of the large NuMA molecule (2115 residues). It is located at the C-terminal end of the predicted first helical subdomain (residues 216-271) of the central rod domain (residues 216-1700). Amino acid replacement studies of the tridecapeptide showed that D259 and R260 do not allow a conservative replacement without loss of antibody reactivity, while some other positions seemed less sensitive.
To explore whether the synthetic peptide including the SPN-3 epitope could adopt an a-helical conformation we measured the CD of peptide 2. The peptide showed no structure in phosphate-buffered saline, but the addition of 50% trifluoroethanol induced 79% a-helix ( Figure 6A ).
Purification and physical properties of the recombinant fragments and of full-length recombinant NuMA protein The cDNA sequence predicts that the NuMA polypeptide contains a long central coiled-coil domain which spans residues 216-1700 and has a length of -220 nm (Parry, 1994 (Table II) , is boxed. The epitope was further characterized using synthetic peptides, each of which contained a single point mutation. Peptides with the single replacement given at the top of the figure showed either no or a very weak reactivity with the SPN-3 antibody. Peptides with the single replacement given at the bottom retained SPN-3 reactivity (for details see Table II ). extracts. Measurement of the sedimentation coefficient in a sucrose gradient, monitored by a dot blot assay, gave a value of 5.7 S. Gel permeation chromatography revealed a viscosity radius of 23 nm. These values suggest that NuMA is an asymmetric rod-like molecule.
Since it was difficult to obtain enough NuMA protein for physical studies from extracts of mitotic HeLa cells, we decided to purify recombinant NuMA fragments, as well as the full-length recombinant NuMA protein, from E.coli and to use this material to study the physical properties of NuMA. Different fragments of NuMA were expressed in the pRSET vector. The pRSET vector is a T7 RNA polymerase-driven expression system that encodes recombinant proteins as fusions with a multifunctional leader peptide containing a hexahistidyl sequence (Histag) to allow purification on Ni2' affinity resins. The leader peptide also contains amino acids 1-12 of the T7 gene 10 major capsid protein, which allows the immunological detection of pRSET-expressed fusion proteins (Kroll et al., 1993) . Since all NuMA derivatives were cloned 5' into the BamHI site of the polylinker, they carried an extra 36 amino acid residues (-4.1 kDa) at the N-terminus.
The recombinant fragments A5, kla, X2b and k2c, as well as the full-length NuMA protein (Figure 1 ), were used in the cross-linking, CD and electron microscopic experiments described below. Chemical cross-linking experiments were used to determine the oligomeric state of the molecules. CD spectroscopy allowed an assessment of the secondary structure and showed that the central domain of NuMA indeed forms an extended cx-helix. Electron microscopy monitored the ultrastructure of the NuMA molecule and its fragments.
AS fragment. The A5 fragment covers amino acid residues 199-432 of NuMA. It includes the C-terminal part of the putative globular head (amino acids 199-215) and the amino terminal part of the putative helix (amino acids 216-432, Figures 1 and 3 ). After induction with isopropylthiogalactoside (IPTG) a 31 kDa polypeptide was expressed at high levels in E.coli (JM109) carrying the pRSET-NuMA 199-432 plasmid ( Figure 3B , lane 1). Most of the A5 fragment was soluble when cells were sonicated in Tween-containing buffer. It was purified by metal chelate affinity chromatography on a Ni-NTA resin followed either by HPLC on a PLRP-S column or by chromatography on a phenylsuperose column. The second purification step provided a homogeneous protein (see Figure 3B , lane 2). The single band of the expected molecular weight seen in SDS-PAGE reacted positively in immunoblots with the SPN-3 antibody ( Figure 3B , lane 3).
Chemical cross-linking experiments were used to determine the oligomeric state of the A5 fragment. The results of such experiments with low concentrations of glutaraldehyde were monitored by SDS-PAGE. Figure 5A shows that increasing concentrations of glutaraldehyde (0.001-0.4%) diminished the normal A5 band at 31 kDa and gave rise to a band with an apparent molecular mass of -64 kDa, corresponding to a dimer. Similar experiments with disuccinimidyl tartrate (DST) and ethyleneglycol bis(succinimidyl succinate) (EGS) also showed that increasing cross-linker concentrations result in the appearance of a dimer band and a corresponding loss of the band in the monomer position. No additional bands at higher molecular masses were observed. Thus the native A5 fragment behaved as a dimer.
The CD spectrum of A5 in 80 mM phosphate buffer showed a substantial negative ellipticity at around 208 and 222 nm, consistent with a high a-helical content ( Figure 6B ). Electron micrographs of a glycerol sprayed/ metal-shadowed A5 preparation documented rod-shaped molecules ( Figure 7A ) with an average length of 33 ± 4 nm (Table III) and a thickness of -2-3 nm. Parallel experiments using the tetrameric rod of the intermediate filament protein desmin, which is around 48 nm in length (Potschka et al., 1990) , confirmed that the A5 molecule is appreciably shorter than the desmin rod (data not shown). Xla fragment. NuMA bp 157-2709, corresponding to amino acids 1-851 (see Figure 1) , were expressed in E.coli, again using the pRSET vector. The Xla fragment covers the entire head domain (residues 1-215) and the N-terminal 43% (residues 216-851) of the putative helical domain. SDS-PAGE showed that after induction with The results of chemical cross-linking experiments with DST and EGS monitored by SDS-PAGE are shown in Figure SC . In the absence of cross-linker (lane 13) fragment Xl a appeared as a single band with the expected molecular mass of the monomer, i.e. 101 kDa. After reaction of Xla with DST at 37°C for 30 min the monomer band gradually disappeared (lanes 1-6) and a band of -200 kDa was seen. Cross-linking of Xla with EGS under the same conditions showed a dimer band even at the lowest concentration of cross-linker used (10 ,ug/ml). The CD spectrum of Xla in phosphate-buffered saline showed the characteristic features of a-helices, with minima at 208 and 222 nm and a maximum at 195 nm ( Figure 6C ). Using the approximation method of Greenfield and Fasman (1969) at 208 nm we calculated an a-helix content of 67%. Based on the sequence of pRSET NuMA 1-851, the presumptive a-helical residues (positions 216-851) account for 72% of the molecule.
Electron microscopy of low angle rotary shadowed Xl a molecules showed thin rods with a small globular 'head' portion at one end ( Figure 7B ). The rod is 92 ± 9 nm in length (Table III) , while the head has a diameter of -14.1 nm (± 1.5 nm). The approximately 3-fold length difference between Xla and A5 corresponds to the increased length of the central rod domain covered by Xla (Table III) show typical a-helical spectra.
protein to be -90%. Electron micrographs of the glycerol sprayed/metal shadowed X2b fragment again showed rodshaped molecules ( Figure 7C ) with an average length of 136 ± 13 nm (Table III) Figure 1 ). After induction with IPTG and cell lysis with Tween, the k2c fragment was insoluble. It was solubilized with 8 M urea buffer containing 10 mM 2-mercaptoethanol and purified under denaturing conditions on the Ni-NTA resin. Subsequent dialysis against phosphate-buffered saline containing 2-mercaptoethanol led to renaturation of the k2c fragment. When subjected to gel filtration on a standardized Superdex 200 column it eluted approximately in the position of ovalbumin (molecular mass 44 kDa). Since the calculated molecular mass of k2c is -49 kDa, the elution profile suggested a globular structure. SDS-PAGE of X2c purified through Superdex showed a single polypeptide band. Electron microscopy of the glycerol sprayed/metal shadowed k2c fragment revealed numerous globular structures and no rod-shaped molecules were detected ( Figure 7D ). The globular structures have a diameter of -14.7 ± 1.4 nm.
Full-length recombinant NuMA. The full-length NuMA cDNA clone covering amino acids 1-2115 (Figure 1 ) was cloned into pRSET and expressed in E.coli. After induction a new polypeptide band appeared in the high molecular weight range (240 kDa) in the total cell lysate of bacteria transformed with the construct ( Figure SD, Thus the rod region may consist of 19 distinct a-helical segments (Parry, 1994 Correlations between the length of rod domains, measured by direct observation, and the length of predicted ca-helical segments have been made for a number of coiled-coil proteins, including myosin (Stewart and Edwards, 1984) , paramyosin (Cohen et al., 1987) , cytoplasmic intermediate filament proteins (Potschka et al., 1990) and nuclear lamins (Heins and Aebi, 1994) . A similar correlation is provided for NuMA in Table III, where the values measured for the different rod constructs described in this study are compared with the lengths derived from the sequence using secondary structure rules and a length of 1.485 A per helical residue. Examination of Table III shows that the calculated lengths are in surprisingly good agreement with the measured lengths.
NuMA has a documented coiled-coil of 207 nm. This value clearly exceeds the myosin coiled-coil of 154 nm (Stewart and Edwards, 1984) and is, indeed, the longest coiled-coil so far reported. Does NuMA form higher order structures? The NuMA protein sequence shares a certain topographical similarity with the sequences of the structural proteins of the cytoplasmic intermediate filaments and of the nuclear lamina (Fuchs and Weber, 1994) . In both cases a central coiled-coil forming domain is flanked by non-helical terminal domains and both cytoplasmic intermediate filament proteins and nuclear lamins can form higher order filaments in vitro. Indeed, because of these similarities in structure and because in interphase NuMA is found in the nuclear matrix, several authors have suggested that NuMA may be a structural component of the nucleoskeleton (Lydersen and Pettijohn, 1980; Kallajoki et al., 1991 Kallajoki et al., , 1993 . Nuclear filaments have been visualized under some conditions in the electron microscope, although their significance is controversial (Cook, 1988) . Filaments, obtained after lysing cells encapsulated in agarose microbeads, nuclease digestion and electroelution of the DNA, have a diameter of around 10 nm, with an axial repeat of 23 nm (Jackson and Cook, 1988) . Alternatively, smooth 9-13 nm nuclear core filaments have been reported after extraction with 0.25 M ammonium sulfate and high salt gradients (He et al., 1990) . Indeed, Zeng et al. (1994) have shown immunoelectron micrographs of a gold-labelled NuMA antibody bound to nuclear filaments prepared by the method of He et al. (1990) . Although this data again raises the question of whether purified recombinant NuMA can polymerize in vitro to form filaments, thus far we have no evidence that this is the case. Under our in vitro conditions recombinant NuMA purified from E.coli neither forms higher order structures nor assembles into filaments, but stays instead as a double-stranded coiled-coil.
There could be several reasons why our in vitro assembly system may not be optimal. (i) The buffer system may be suboptimal for assembly; (ii) renaturation of the globular head and tail domains of NuMA from 8 M urea may be incomplete; (iii) the recombinant NuMA molecules contain 36 additional residues in front of the head domain due to the cloning system used and this tag could interfere with assembly; (iv) putative higher order structure may require post-translational modification(s) and/or processing which is not provided by recombinant protein expression in E.coli. Some of these potential shortcomings can be overcome in the future. Thus a highly specific cleavage site could be used to remove the entire tag from the purified protein by specific proteolysis. Alternatively, NuMA could be expressed with the bacculovirus system in insect cells to see whether eukaryotic post-translational modifications are important. Currently it is more difficult to see how renaturation of the terminal domains could be improved, since recombinant NuMA is insoluble in normal buffer and thus has to be purified in 8 M urea. However, one possibility could be to use chaperones during the renaturation process.
Alternatively, NuMA may indeed not be able to form filaments on its own. Thus a detailed analysis of the distribution of positive and negative charges along the helical arrays reveals a lack of the typical periodicities found in corresponding regions of filament forming molecules such as myosin II, paramyosin and the structural proteins of intermediate filaments, where filament forming ability is based on lateral and longitudinal interactions of coiled-coils (Parry, 1994) . While these observations, as well as our current results, provide no support for NuMA as a major constituent of nuclear filaments, they leave open the possibility that NuMA may form higher order complexes containing several dimeric molecules or that NuMA may form specific complexes with other cellular proteins. Indeed, the established functional significance of NuMA in the mitotic spindle (Kallajoki et al., 1991 (Kallajoki et al., , 1993 and its insolubility in the interphase nuclear matrix (Lyderson and Pettijohn, 1980; Kallajoki et al., 1991) directly argue for binding to other cellular components. This problem could be approached by use of the two-hybrid system (Chien et al., 1991 (Compton et al., 1992) . Only the SPN-4 epitope, mapped to the region between NuMA residues 199 and 216, lies at the C-terminal end of the globular head domain just prior to the x-helical rod.
The epitope of the SPN-3 NuMA monoclonal antibody was of particular interest because this antibody inhibited mitosis and led to micronucleation when injected into cells, while the SPN-1, -2, -4 and -5 antibodies did not (Kallajoki et al., 1991) . Use of several recombinant NuMA clones and subclones located the SPN-3 epitope to the Nterminal part of the rod domain (residues 247-279) and a set of synthetic peptides refined the analysis. The SPN-3 epitope is a linear epitope which arises from the tridecapeptide covering residues 255-267 of the human NuMA polypeptide. This sequence directly preceeds the first nonhelical spacer of the rod domain (Figure 2 ). Mutant peptides with single amino acid replacements identified several positions of the epitope with very strict sequence requirements. Interestingly, neither Asp259 nor Arg260 tolerate the highly conservative replacement by Glu or Lys respectively (Figure 4 ). This high sequence dependence may contribute to the relatively limited cross-species reactivity of the SPN-3 antibody (Kallajoki et al., 1991) and may become more obvious once NuMA sequences from additional species become available.
Our results do not explain why SPN-3 was the only monoclonal antibody of those tested which inhibited mitosis after microinjection. McIntosh and Koonce (1989) have compiled a list of spindle components and commented that a monoclonal antibody affected microinjection in only very few cases. Thus it seems that various monoclonal antibodies either do not find access to their epitope within the living cell or do not have a sufficiently high affinity to stay bound at the epitope. Alternatively, occupation of the epitope by the antibody may not necessarily exert a perturbing effect on mitosis. In this respect we note that an antibody molecule can cover on its antigen some 3 nm in length, which on a coiled-coil would correspond to some 20 x-helical residues (Colman et al., 1987) .
Effects similar to those first demonstrated for the SPN-3 NuMA antibody in microinjection experiments, i.e. mitotic arrest with perturbed mitotic spindle formation and formation of micronuclei (Kallajoki et al., 1991) , have also been observed by others. Thus injection of a rabbit antibody directed against an 85 kDa recombinant fragment of the NuMA rod (GST:2) into interphase or prophase monkey CV-I cells blocked formation of the mitotic spindle, while injection of the same antibody into metaphase cells caused the preformed spindle to collapse . Interestingly, the GST:2 fragment corresponds approximately to the C-terminal two thirds of segment 3 and segment 4 and therefore does not contain the SPN-3 epitope site. In addition, transfection of NuMA constructs lacking amino acids 19-208 results in BHK-21 cells that fail to complete cytokinesis and form micronuclei in the subsequent interphase. In contrast, NuMA constructs lacking the globular tail domain result in cells that complete mitosis but then form micronuclei in each daughter cell (Compton et al., 1992) . Interestingly, the defect in the hamster tsBN2 cell line, which forms micronuclei at the restrictive temperature, can be rescued by transfection with human NuMA (Compton and Cleveland, 1993 
Materials and methods

Immunoscreening
The screen was performed as described for a lamin cDNA clone (Stick, 1988) (Stratagene, Heidelberg, Germany) . A total of 1 800 000 clones were screened with a mixture of the hybridoma supernatants from six previously characterized antibodies to the SPN/NuMA antigen, i.e. SPN-1 to -5 and SPN-7 (Kallajoki et al., 1991) , after induction of the 3-galactosidase fusion proteins by 10 mM IPTG (Biomol, Hercules, CA). The antibody incubation was carried out with a mixture of supernatants from the six SPN/NuMA antibodies, to which 0.05% Tween-20 and 0.1I% pig haemoglobin were added. Antibody-reactive clones were visualized using as second antibody alkaline phosphatase-conjugated goat anti-mouse antibodies (Dianova, Hamburg Germany; 1:2 000 in TBS-T buffer) and as developing solution 0.33 mg/ml nitrobluetetrazolium (NBT) and 0.2 mg/ml bromochloroindolyl phosphate (BCIP; Sigma, St Louis, MO) in 0.1 M Na2CO3, pH 10.2. Positive plaques were picked, replated at lower density and rescreened. This procedure was repeated until all phages on the plate were immunoreactive with the antibody mixture. Reactivity with each individual NuMA monoclonal antibody was subsequently analysed.
The screening yielded a total of seven immunoreactive clones, five from the k ZAP II library (kl-X5) and two from the Uni-ZAP XR library . Bluescript SK phagemids containing the cloned cDNA insert of the immunoreactive phages were excised by co-infection with the R408 helper phage according to the manufacturer's protocol (Stratagene) and purified by standard protocols. Sequencing was performed by the dideoxy chain termination reaction according to Sanger et al. (1977) . T3 and T7 primers, as well as specific primers derived from the NuMA sequence of , were employed.
Expression of /3-galactosidase fusion proteins X phages were diluted to a concentration sufficient for plaques to form a nearly confluent monolayer after 8 h at 42°C. IPTG (50 mM) was then added and the plates incubated for a further 3 h at 37°C. SDS sample buffer was then added and the samples harvested, heated to 100°C and used for SDS-PAGE.
Construction of full-length and partial NuMA cDNAs
Since the immunoscreen of the cDNA libraries yielded only partial NuMA cDNAs, full-length NuMA cDNA was constructed from the two overlapping clones kl and k2 (Figure 1 ). These spanned nucleotides 65-2710 and 2163-7145 respectively (Kroll et al., 1993) . Thus the N-terminal sequences of the NuMA derivatives are preceeded by 36 residues encoded by the expression vector.
Additional truncated mutants of Xl (Xlb, klc and kid) and the X2 clone (X2b and k2c) (see Figure 1) were constructed in a similar manner using Xl or X2 as templates. PCR used Vent polymerase (New England Biolabs, Beverly, MA), which ensured high fidelity base incorporation due to its 3'-5' proof-reading exonuclease activity. Primer pairs were as follows: kla (33, 36) , klb (33, 20) , klc (27, 36) , kld (27, 37), X2a (34, 38), k2b (34, 39) , X2c (35, 38 ) (see Table IV , where the numbers indicate the nucleotide positions of NuMA taken from the cDNA sequence of . Some PCR amplified products were first subcloned in the pCRII vector (Invitrogen) and released by cleavage with BamHI/HindII or with BamHI/EcoRI digestion before ligation into the appropriate restriction site in the pRSETA vector.
For mapping of the SPN-3 epitope a series of NuMA pRSET expression plasmids was generated by amplifying different regions of NuMA cDNA from the Uni-l clone plasmid DNA using Taq DNA polymerase (Promega, Madison WI). Primer pairs were as follows: Al (17, 20), A2 (18, 21) , A3 (19, 22) , A4 (17, 21) , A5 (18, 22), Nl (18, 30) , N2 (27, 31), N3 (28, 32), N4 (29, 21) , N5 (18, 31), N6 (28, 21) , N7 (27, 32) (see Table IV ). All final products were cloned in-frame with the fusion protein part of the pRSET vector by an appropriate choice of the 5'-end primers.
Overexpression of fusion proteins
Two millilitres of SOB containing ampicillin at 50,g/ml were inoculated with a single recombinant Ecoli JM 109 colony harbouring the appropriate plasmid and grown overnight at 37°C with shaking. Aliquots (0.8 ml) of this overnight culture was used to inoculate 200 ml of SOB medium containing 50 ,tg/ml ampicillin. Cultures were then grown with shaking at 37°C until they reached an optical density at 600 nm of 0.3. Overexpression of the recombinant protein was initiated by adding I mM IPTG. One hour later cells were infected with M 13/T7 phage at a multiplicity of infection of 5 plaque-forming units/cell, incubated for an additional 4 h to permit maximal expression of fusion proteins and harvested by centrifugation (4000 g for 20 min).
Purification of recombinant proteins
Cells from three 200 ml cultures were resuspended in 10 ml lysis buffer (50 mM potassium phosphate, pH 7.9, 500 mM KCI, 10 mM 2-mercaptoethanol, I mM phenylmethylsulfonyl fluoride, 0.2% Tween 20) and sonicated. The lysate was clarified by centrifugation at 10 000 g for 15 min.
In the case of NuMA derivatives which were soluble in lysis buffer the supernatant was applied directly to Ni-NTA resin (Quiagen, Chatsworth, CA), packed in a chromatography column and equilibrated in lysis buffer. The flow through was usually re-applied to the column and a flow rate of 2-5 ml/h was used. The resin was washed with lysis buffer. The second wash was with lysis buffer, pH 6.0, containing up to 20 mM imidazole. Proteins were eluted in the same buffer using a 20-500 mM imidazole gradient.
For NuMA derivatives insoluble in lysis buffer the pellet was treated with urea buffer (8 M urea, 20 mM Tris-HCI, pH 7.9, 500 mM NaCI, 10 mM 2-mercaptoethanol). After sonication and centrifugation the supernatant was also fractionated by metal chelate affinity chromatography on Ni-NTA resin (Quiagen). The column was washed with urea buffer, followed by a second wash with urea buffer, pH 6.3, containing 5 mM imidazole. Proteins were eluted in the same buffer using a 5-500 mM imidazole gradient.
Fractions were monitored spectrophotometrically and analysed by SDS-PAGE. After identification of the fractions containing the recombinant protein, the proteins were further purified. Fusion protein N3 was purified by HPLC on a Vydac 214 TP52 column; fusion protein A5 was purified either by HPLC (PLRP-S column) or by a phenylsuperose column (50 mM MES, pH 6, 1 mM EDTA, 0.3 mM dithiothreitol), using a gradient of 1-0 M (NH4)2SO4; fusion proteins kla and X2b were purified by gel filtration on Superdex 200 under native conditions; fusion protein k2c and the full-length NuMA protein (FL) were purified by gel filtration in the presence of 8 M urea on Superdex 200 (Pharmacia) or TSK 6000 PW (Toso Haas). Full-length NuMA was further purified by Mono-Q chromatography in the presence of 8 M urea.
Cross-linking
Fragment A5, purified by HPLC at a concentration of 30-4() g/ml, was dialysed for 12 h at 4°C against phosphate-buffered saline (PBS) containing 2.5 mM dithioerythritol. Glutaraldehyde (Serva, Heidelberg, Germany) was added to aliquots such that final concentrations ranged from 0.001 to 0.04%. Samples were incubated for 30 min at 14°C. The cross-linking reactions were terminated by addition of one half volume of the same buffer containing 2 M glycine. Cross-linked samples were resolved by SDS-PAGE using 4-12% gradient gels.
The fusion protein kl a was dialysed against 50 mM triethanolamine-HCI, pH 8.0, containing 0.17 M NaCl and I mM 2-mercaptoethanol. The protein concentration was adjusted to -0.1 mg/ml. EGS or DS1 (both from Pierce) were dissolved in dimethylsulfoxide at 7.5 mg/ml. Cross-linker was added to the protein solution to final concentrations ranging from 0 to 1 mg/ml. Cross-linking was for 30 min at 37°C. Reactions were stopped by adding ethanolamine-HCI, pH 8.0, to a final concentration of 0.1 M for 15 min at room temperature. The EGS or DST cross-linked material was directly applied to SDS-PAGE.
Circular dichroism
The AS fragment was dialysed against 80 mM potassium phosphate, pH 7.0, while the other purified fusion proteins were dialysed against Glycerol was added to the protein solutions to a final concentration of 50%. The protein solutions were then sprayed on to freshly cleaved mica flakes, which were subsequently dried under vacuum. Rotary shadowing with tantalum/tungsten or platinum was performed at an angle of 5°or 90 respectively using a modified Balzers apparatus followed by carbon shadowing at 90°. Replicas were floated off on a surface of distilled water and collected on copper grids (400 mesh, TAAB, Munich).
Gel filtration analysis
Analytical gel filtration chromatography was performed using the SMART micro FPLC facility (Pharmacia, Uppsala, Sweden) and a Superdex 200 HR 10/30 gel filtration column (Pharmacia) equilibrated in PBS containing mM dithiothreitol. Proteins were separated at a flow rate of 40 ,tl/min at room temperature. Elution profiles were monitored at 280 nm. The system was calibrated with molecular weight standards (Bio-Rad, Munich, Germany).
SDS gel electrophoresis and immunoblotting SDS-PAGE was performed in 0.5 mm thick slab gels containing 10% acrylamide. In some experiments gradient gels with 4-12%/e acrylamide or tricine gels with a spacer gel of 1 0%/3% and a separating gel of 16.5%/ 3% were used (Schaigger and von Jagow, 1987 Milligen) based on protection of the amino group with 9-fluorenyl methoxycarboxyl. Synthesis and deprotection followed the standard protocol of the manufacturer. Peptides were purified by HPLC on a preparative reverse-phase column (Vydac 218 Tp. 10 gm). Sequence identity was verified by automated gas phase sequencing on an Applied Biosystems gas phase sequenator (model A470) or a Knauer sequenator (model 810). Both instruments were equipped with an on-line phenylthiohydantoin amino acid analyser. The exact peptide concentrations were determined by quantitative amino acid analysis. After hydrolysis in propionic acid/HCl at 150°C for 1 h, amino acids were subjected to pre-column derivatization with phenylisothiocyanate (Bidlingmeyer et al., 1984) and analysed on a HPLC reverse phase column. The peptide stocks were then adjusted to a concentration of 2 mM in PBS and stored at -20°C until use.
Coupling of peptides to ovalbumin
Twenty five milligrams of ovalbumin (Sigma) in I ml PBS and 9 mg m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (Sulfo-MBS; Pierce, Rockford, IL) in 0.5 ml PBS were mixed and incubated with rotation for 30 min at room temperature. Uncoupled Sulfo-MBS was removed on a PD 10-column equilibrated with 50 mM sodium phosphate buffer, pH 6. Usually -2.5 ml of ovalbumin-Sulfo-MBS was obtained. Five milligrams of purified peptide in 4 ml PBS was mixed with 500 p1 ovalbumin-Sulfo-MBS fraction from the PD 10 column and 300 tl 0.5 M sodium phosphate buffer, pH 7.5. Incubation was for 3 h at room temperature on a rocking platform. The coupled peptides were either used directly in the dot blot assay or stored at -20(C.
Competitive ELISA
The recombinant fusion protein kla was used as the antigen. It was diluted to a final concentration of 0.6 pg/mI with coating buffer (15 mM Na2CO3, 35 mM NaHCO3). A 50 p1 aliquot containing 30 ng Ala protein was pipetted into each well of a 96-well microtitre plate (Immunolon F-Form; Dynatech, Denkendorf, Germany) . Plates were incubated overnight at 4°C and then for 30 min at room temperature. The plates were washed three times with PBS, blocked for 2 h at 37°C with PBS containing 4% bovine serum albumin (BSA) and then washed three times with PBS. A dilution series was made for each peptide in PBS containing 1 % BSA, so that end concentrations were between i0-7 and 10-3 M. These were preincubated with an equal volume of the SPN-3 monoclonal antibody (SPN-3 hybridoma supernatant diluted 1: 100 in the same buffer) for 30 min at room temperature. The different peptide/antibody mixtures (50 p1) were pipetted into the microtitre plates containing kla and incubated for 1.5 h at 37°C. Subsequently the wells were washed three times with PBS and incubated for 1.5 h at 370C with the second antibody (peroxidase-conjugated rabbit anti-mouse diluted 1:4(0) in PBS containing 1% BSA; Dako, Klostrup, Denmark). The wells were washed again with PBS and 100 gI of freshly prepared developing solution were added [10 mg o-phenylene diamine dissolved in 25 ml of buffer (25 mM sodium citrate, 50 mM Na2HPO4 pH 5.0) to which 10 ,l 30% H202 were added just before usel and incubation continued for 10 min at room temperature. The reaction was stopped with 2.5 M sulfuric acid and the optical density was measured at 490 nm using an ELISA reader (Dynatech, Model MR 700).
